Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
24 Abril 2024 - 6:00AM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose
mission is to develop medicines that meaningfully improve and
extend the lives of patients facing deadly diseases, today
announced that it will host a live conference call and audio
webcast on Wednesday, May 1, 2024 at 8:30 a.m. ET to report
financial results for the first quarter ended March 31, 2024, and
to provide a business overview.
To access the live conference call, please dial (646) 307-1963
(domestic) or (800) 715-9871 (international) at least five minutes
prior to the start time, and refer to conference ID 1246220. A live
audio webcast of the call will also be available on the Investors’
section of the Company's website, www.chimerix.com. An archived
webcast will be available on the Chimerix website approximately two
hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to
develop medicines that meaningfully improve and extend the lives of
patients facing deadly diseases. The Company’s most advanced
clinical-stage development program, ONC201, is in development for
H3 K27M-mutant glioma.
CONTACT: Will
O’ConnorStern Investor Relations212-362-1200will@sternir.com
Chimerix (NASDAQ:CMRX)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Chimerix (NASDAQ:CMRX)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024